Aslan Pharmaceuticals Stock Debt To Equity
Aslan Pharmaceuticals fundamentals help investors to digest information that contributes to Aslan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Aslan Stock. The fundamental analysis module provides a way to measure Aslan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Aslan Pharmaceuticals stock.
Aslan |
Aslan Pharmaceuticals Company Debt To Equity Analysis
Aslan Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Aslan Pharmaceuticals Debt To Equity | 1.12 % |
Most of Aslan Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Aslan Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Aslan Pharmaceuticals has a Debt To Equity of 1.116%. This is 97.92% lower than that of the Biotechnology sector and 94.24% lower than that of the Health Care industry. The debt to equity for all United States stocks is 97.71% higher than that of the company.
Aslan Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aslan Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Aslan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aslan Pharmaceuticals by comparing valuation metrics of similar companies.Aslan Pharmaceuticals is currently under evaluation in debt to equity category among its peers.
Aslan Fundamentals
| Return On Equity | -4.27 | |||
| Return On Asset | -0.54 | |||
| Profit Margin | (2.92) % | |||
| Operating Margin | (2.91) % | |||
| Current Valuation | 288.33 M | |||
| Shares Outstanding | 2.83 M | |||
| Shares Owned By Insiders | 0.14 % | |||
| Shares Owned By Institutions | 13.21 % | |||
| Number Of Shares Shorted | 306.56 K | |||
| Price To Earning | (11.50) X | |||
| Price To Book | 2.14 X | |||
| Price To Sales | 0.94 X | |||
| Revenue | 12 M | |||
| Gross Profit | 79.82 M | |||
| EBITDA | (43.39 M) | |||
| Net Income | (44.22 M) | |||
| Cash And Equivalents | 78.12 M | |||
| Cash Per Share | 1.12 X | |||
| Total Debt | 26.83 M | |||
| Debt To Equity | 1.12 % | |||
| Current Ratio | 6.97 X | |||
| Book Value Per Share | (7.70) X | |||
| Cash Flow From Operations | (46.36 M) | |||
| Short Ratio | 1.85 X | |||
| Earnings Per Share | (16.00) X | |||
| Target Price | 72.0 | |||
| Number Of Employees | 35 | |||
| Beta | 1.4 | |||
| Market Capitalization | 1.7 M | |||
| Total Asset | 24.63 M | |||
| Retained Earnings | (321.07 M) | |||
| Working Capital | 11.02 M | |||
| Current Asset | 54.61 M | |||
| Current Liabilities | 5.15 M | |||
| Net Asset | 24.63 M |
Pair Trading with Aslan Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Boston Scientific could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Boston Scientific when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Boston Scientific - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Boston Scientific Corp to buy it.
The correlation of Boston Scientific is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Boston Scientific moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Boston Scientific Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Boston Scientific can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Consideration for investing in Aslan Stock
If you are still planning to invest in Aslan Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aslan Pharmaceuticals' history and understand the potential risks before investing.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |